Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Clin Cancer Res. 2010 Aug 1;16(15):3954–3963. doi: 10.1158/1078-0432.CCR-10-0368

Figure 3. EMP2 expression in human ovarian cell lines.

Figure 3

(A) Equivalent amounts of cell lysates from all 12 cell lines, as indicated, were immunoblotted with EMP2 antisera. The same blot was re-probed using a monoclonal anti-β-actin antibody. The ratio of EMP2/β-actin was calculated by scanning quantities of EMP2 and β-actin. As a positive control, EMP2 expression was assessed in the cervical cancer cell line (HeLa) and the endometrial carcinoma cell line RL95-2. (B) To determine the surface expression of EMP2, ovarian cancer cells were stained and analyzed by flow cytometry. High EMP2 expression is detectable on the plasma membrane of OVCAR5 cells using an EMP2 diabody KS83. Lower levels of EMP2 were detected on the membrane of OVCA433 cells. As a negative control, no EMP2 was found on OV90 cell surface. An isotype control (diabody A10) was used to show specificity of binding.